IonStar could upend industry standards, and quicken medical diagnosis and drug development
A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.
The groundbreaking tool, called IonStar, is the first to provide near-perfect accuracy when quantifying and comparing the abundance of proteins in the bodies of people who are healthy and ill.
Compared to industry standard MaxQuant, IonStar improved the measurement consistency of proteins in low abundance and lowered the amount of missing data in results from 17 percent to 0.1 percent, a level that has never been achieved with large samples.
The new tool could increase the quality and accuracy of medical diagnosis and quicken the pace of pharmaceutical development.
“IonStar will totally change the face of clinical and pharmaceutical research and industry, where large investigations are often critical,” says Jun Qu, PhD, lead investigator and professor in the UB School of Pharmacy and Pharmaceutical Sciences.
The research was published yesterday in the Proceedings of the National Academy of Sciences (PNAS).
Playing spot the difference
The abundance of proteins in the body that correspond with disease or pharmaceutical reactions can provide researchers with vital clues for accurately diagnosing a condition, and for developing potential therapies and evaluating drug effects.
Protein analysis tools are used to quantify and compare the abundance of proteins in groups of healthy individuals with those who are ill or treated with a drug. Changes in protein abundances, when analyzed together, often reveal novel biomarkers.
The challenge for researchers is that current tools are not efficient at analyzing large numbers of samples. One type of method, the labeling-method, uses chemical tags to label proteins. The issue: The software can only analyze up to 10 samples at a time, making it difficult for researchers to conduct typical pharmaceutical and clinical studies, says Qu.
The alternative, the label-free method, can analyze a large number of samples at once at the expense of accuracy and precision, causing researchers to waste time and resources validating falsely identified biomarkers.
IonStar increases accuracy and precision and lowers missing data by improving on sample preparation methods, alignment and feature detection designs for mass spectrometry analysis.
“For example, in clinical trials, comparing a handful of patients gets you nowhere,” says Qu. “If you can analyze a large number of patients with high-quality data, you can discover and track biomarkers much more accurately and reliably. The same is true for pharmaceutical investigations.”
Proving the concept in traumatic brain injury
Researchers used IonStar to quantify proteins in rats with traumatic brain injury, a debilitating condition that accounts for 2.2 million emergency room visits annually in the United States.
Using 100 tissue samples, IonStar identified 7,000 proteins, including 1,000 that differed in abundance, without missing data.
IonStar also measured low-abundance proteins with higher accuracy and precision than other prevalent analysis tools. This capability is critical, says Qu, because proteins that appear in smaller amounts play a more influential role in the body.
“If higher-level proteins are soldiers, then lower-level proteins are the commanders. They are the regulators that tell the higher-level proteins what to do,” says Qu.
Qu has used IonStar and similar techniques to analyze protein variation in cancer, diabetes, cardiovascular disease, neurodegeneration and retina degeneration as well.
Future work on IonStar will focus on expanding the number of samples the tool can analyze.
The Latest on: Drug development
via Google News
The Latest on: Drug development
Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development
on August 15, 2018 at 5:00 am
CHARLOTTESVILLE, Va., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent f... […]
Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit
on August 15, 2018 at 5:00 am
Data demonstrates continued efficacy of marzeptacog alfa (activated) in two additional subjects SOUTH SAN FRANCISCO, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), ... […]
5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them
on August 15, 2018 at 3:02 am
BioThrax is currently the only anthrax vaccine approved by the U.S. Food and Drug Administration (FDA ... its ResVax vaccine is far along the development path. Novavax recently announced that it achie... […]
As Alzheimer’s drug developers give up on today’s patients, where is the outrage?
on August 15, 2018 at 1:43 am
the smart money says that is more likely to come from a drug that prevents the development of full-on dementia in people with mild cognitive impairment or even just risk factors (including genetic one... […]
Drug therapy and other factors associated with the development of acute kidney injury in critically ill patients: a cross-sectional study
on August 14, 2018 at 5:25 pm
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for ... […]
Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit
on August 13, 2018 at 5:00 am
A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website once the presentation concludes. Catalyst is a clinical-stage biopharmaceutical com... […]
Drugs in Development for Cancer May Also Fight Brain Diseases
on August 10, 2018 at 1:53 am
In cells under duress, stress granules (in magenta) form outside of the nucleus (in blue). TDP-43 protein in green (arrow) that cannot bind to PolyADP ribose (PAR) builds up in large clumps distinct f... […]
Drugs in development for cancer may also fight brain diseases, including ALS
on August 9, 2018 at 2:36 pm
A class of cancer drugs called PARP inhibitors could be useful for treating and preventing brain disorders, including ALS (Lou Gehrig's disease) and some forms of frontotemporal degeneration, by halti... […]
FDA issues scientific recommendations to encourage development of novel drugs for treatment of OUD
on August 6, 2018 at 10:39 pm
The U.S. Food and Drug Administration today issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for ... […]
via Bing News